|
|
|
| 
|
|
|
My Recent Searches
|
|
|
|
|
|
|
|
|
Guardant Health, Inc. (GH) |
|
|
$0.00 0.00 (0.00%) as of 4:30 Fri 2/14
|
|
Download |
|
|
| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
121,380,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0 - $0 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Guardant Health is a precision oncology company focused on helping conquer cancer globally through use of its proprietary blood-based tests, data sets and analytics. Co. is engaged in the clinical liquid biopsy market with its Guardant360 and GuardantOMNI tests. Co.'s Guardant360 test is a molecular diagnostic test measuring a number of cancer-related genes and its GuardantOMNI test has a 500-gene panel, both of which analyze circulating tumor DNA in blood. In addition, Co. is developing tests from its LUNAR-1 program for minimal residual disease and recurrence detection in cancer survivors, and its LUNAR-2 program for early detection of cancer.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
2,187 |
2,187 |
98,220 |
| Total Buy Value |
$0 |
$38,963 |
$38,963 |
$2,585,297 |
| Total People Bought |
0 |
1 |
1 |
2 |
| Total Buy Transactions |
0 |
1 |
1 |
4 |
| Total Shares Sold |
100 |
200 |
8,325 |
31,716 |
| Total Sell Value |
$2,787 |
$4,692 |
$233,035 |
$1,293,892 |
| Total People Sold |
1 |
1 |
2 |
3 |
| Total Sell Transactions |
1 |
2 |
6 |
12 |
| End Date |
2024-03-28 |
2023-12-26 |
2023-06-27 |
2022-06-27 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Wiley Michael J |
Chief Legal Officer |
• – – |
2019-08-01 |
4 |
A |
$0.00 |
$0 |
D/D |
5,758 |
271,737 |
|
- |
|
| Bertocci Derek A |
Chief Financial Officer |
• – – |
2019-08-01 |
4 |
A |
$0.00 |
$0 |
D/D |
5,758 |
99,962 |
|
- |
|
| Svf Endurance (cayman) Ltd |
10% Owner |
– – • |
2019-07-05 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
27,850,460 |
|
- |
|
| Kaul Samir |
Director |
– • – |
2019-06-18 |
4 |
A |
$0.00 |
$0 |
D/D |
1,302 |
1,302 |
|
- |
|
| Clark Ian T |
Director |
– • – |
2019-06-18 |
4 |
A |
$0.00 |
$0 |
D/D |
1,302 |
1,302 |
|
- |
|
| Hilaly Aaref |
Director |
– • – |
2019-06-18 |
4 |
A |
$0.00 |
$0 |
D/D |
1,302 |
1,302 |
|
- |
|
| Nishar Dipchand |
Director |
– • – |
2019-06-18 |
4 |
A |
$0.00 |
$0 |
D/D |
1,302 |
1,302 |
|
- |
|
| Meresman Stanley J |
Director |
– • – |
2019-06-18 |
4 |
A |
$0.00 |
$0 |
D/D |
1,302 |
1,302 |
|
- |
|
| Lanman Richard B. |
Chief Medical Officer |
• – – |
2019-05-16 |
4 |
AS |
$80.00 |
$135,200 |
D/D |
(1,690) |
129,729 |
|
- |
|
| Eltoukhy Helmy |
Chief Executive Officer |
• • – |
2019-05-14 |
4 |
AS |
$72.05 |
$5,690,187 |
D/D |
(78,660) |
3,986,965 |
|
- |
|
| Eltoukhy Helmy |
Chief Executive Officer |
• • – |
2019-05-14 |
4 |
OE |
$4.18 |
$105,566 |
D/D |
25,255 |
4,065,625 |
|
- |
|
| Bertocci Derek A |
Chief Financial Officer |
• – – |
2019-05-10 |
4 |
AS |
$72.33 |
$1,416,317 |
D/D |
(18,562) |
92,875 |
|
- |
|
| Bertocci Derek A |
Chief Financial Officer |
• – – |
2019-05-10 |
4 |
OE |
$3.63 |
$67,380 |
D/D |
18,562 |
111,437 |
|
- |
|
| Wiley Michael J |
Chief Legal Officer |
• – – |
2019-05-08 |
4 |
AS |
$65.54 |
$5,276,555 |
D/D |
(80,000) |
265,358 |
|
- |
|
| Clark Ian T |
Director |
– • – |
2019-05-03 |
4 |
AS |
$65.91 |
$177,298 |
D/D |
(2,690) |
0 |
|
- |
|
| Clark Ian T |
Director |
– • – |
2019-05-03 |
4 |
OE |
$4.18 |
$11,244 |
D/D |
2,690 |
2,690 |
|
- |
|
| Lanman Richard B. |
Chief Medical Officer |
• – – |
2019-05-01 |
4 |
AS |
$64.49 |
$249,127 |
D/D |
(3,842) |
131,419 |
|
- |
|
| Lanman Richard B. |
Chief Medical Officer |
• – – |
2019-05-01 |
4 |
OE |
$4.18 |
$26,713 |
D/D |
3,842 |
135,261 |
|
- |
|
| Eltoukhy Helmy |
Chief Executive Officer |
• • – |
2019-05-01 |
4 |
AS |
$64.15 |
$2,691,149 |
I/I |
(41,721) |
0 |
|
- |
|
| Eltoukhy Helmy |
Chief Executive Officer |
• • – |
2019-04-30 |
4 |
AS |
$65.52 |
$5,888,037 |
I/I |
(89,619) |
13,907 |
|
- |
|
| Clark Ian T |
Director |
– • – |
2019-04-25 |
4 |
AS |
$65.11 |
$35,029 |
D/D |
(538) |
0 |
|
- |
|
| Clark Ian T |
Director |
– • – |
2019-04-25 |
4 |
OE |
$4.18 |
$2,249 |
D/D |
538 |
538 |
|
- |
|
| Talasaz Amirali |
Chairman, President and COO |
• • – |
2019-04-24 |
4 |
AS |
$65.30 |
$523,832 |
D/D |
(7,932) |
1,960 |
|
- |
|
| Talasaz Amirali |
Chairman, President and COO |
• • – |
2019-04-24 |
4 |
OE |
$4.18 |
$31,158 |
D/D |
7,454 |
9,892 |
|
- |
|
| Talasaz Amirali |
Chairman, President and COO |
• • – |
2019-04-24 |
4 |
AS |
$65.28 |
$1,985,561 |
I/I |
(30,064) |
13,333 |
|
- |
|
707 Records found
|
|
Page 27 of 29 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
